Abstract: This application provides a classification method, device and storage medium. The classification method includes obtaining text to be processed; and processing the text to be processed based on a text classifier to obtain category information corresponding to the text, wherein the text classifier is generated based on classification guidance information and a generative pre-trained model, and the generative pre-trained model generates target classification data and its corresponding label information needed to train the text classifier based on the classification guidance information.

Abstract: A lattice-based proxy signature method, apparatus and device, a lattice-based proxy signature verification method, apparatus and device, and a storage medium. Polynomials are randomly selected in rings to calculate public and private keys of nodes, and the magnitudes of proxy public and private keys are the same as the magnitudes of public and private keys of an original signer. Therefore, compared with existing proxy signature schemes, the present application has smaller lengths of public and private keys and higher storage efficiency. Proxy signature information generated in the present application shows a signature of the original signer and also shows a signature of a proxy signer. Once a proxy signature is created, the proxy signature cannot be repudiated by the proxy signer, and has strong non-repudiation and strong unforgeability. The proxy signature method has the advantage of resisting quantum computer attack.

Abstract: An electrochemical device includes an electrode assembly, a housing, a sealing member, and a tab. The housing includes a main body portion and a sealing portion. At least a portion of the sealing member is disposed in the sealing portion, and the sealing member includes a first sealing member and a second sealing member. The tab protrudes from the sealing portion and is arranged between the first sealing member and the second sealing member. The first sealing member includes a first sealing layer and a second sealing layer disposed on the first sealing layer, and the first sealing layer is located between the tab and the second sealing layer. A melting point of the first sealing layer is lower than that of the second sealing layer, and a difference in the melting point between the first sealing layer and the second sealing layer is 35° C. to 50° C.

Abstract: Embodiments of the present disclosure concern methods and compositions for prognosis, diagnosis, and/or treatment of prostate cancer or breast cancer, for example. Certain embodiments of the disclosure concern assaying for the expression level of TDRD1. Particular embodiments concern treating an individual with a particular cancer therapy when the expression level of TDRD1 is overexpressed.

Abstract: The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.

Abstract: Embodiments of the present disclosure concern methods and compositions for prognosis, diagnosis, and/or treatment of prostate cancer or breast cancer, for example. Certain embodiments of the disclosure concern assaying for the expression level of TDRDl. Particular embodiments concern treating an individual with a particular cancer therapy when the expression level of TDRDl is overexpressed.

Abstract: The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.

Abstract: The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.

Abstract: The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.

Abstract: The present invention relates to a peptide for anti-angiogenesis and use thereof, in particular, to a peptide useful for treating angiogenesis diseases; a polynucleotide coding the peptide; a vector and a cell comprising the polynucleotide; a pharmaceutical composition comprising the peptide, the fused peptide or the fused protein, the polynucleotide, the vector and/or the cell. The peptide, the fused peptide or the fused protein, the polynucleotide, the vector, the cell and/or the pharmaceutical composition can be used for treatment of associated diseases such as tumor by anti-angiogenesis.

Abstract: The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.

Abstract: A pharmaceutical composition for treatment of chronic liver diseases, the composition including at least cordyceps sinensis polysaccharide, amygdaloside, and gypenoside. The pharmaceutical composition slows down liver fibrosis, stops the development thereof, or reverses the same. A method of using the pharmaceutical composition for treatment of chronic liver diseases.

Abstract: The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.

Abstract: The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.

Abstract: The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.